Empowering every scientist to turn science into venture-ready opportunities.

AI-powered commercialization maturity assessment that accelerates investments in science and deep-tech.

Schedule a Demo

Our frameworks driving innovation at major organizations. We are now turning them into a scalable platform for effective innovation management and investment

NIST logo with stylized black and white design.
Logo of the University of North Carolina at Chapel Hill with a depiction of the university's iconic bell tower.
Black and white NASA logo with a circular shape, stylized stars, and orbit lines around the NASA text.
UNMC logo with the text 'University of Nebraska Medical Center'
Saudi Aramco logo on a black background with Arabic and English text
Logo of King Abdullah University of Science and Technology with Arabic and English text
Logo of Imam Abdulrahman Bin Faisal University with Arabic and English text
Logo of ART International in black and white.
A logo with a black background featuring a stylized crown and a geometric design.
DARPA logo with a globe design

THE PROBLEM

SCIENTIFIC DUE DILIGENCE IS BROKEN

routine

Manual
Most diligence is still spreadsheet-driven and expert-dependent—weeks to months of interviews, document chasing, and narrative synthesis.

extension

Complex
Multidisciplinary by nature: beyond tech maturity, it requires evaluating IP, regulatory, reimbursement, competition, manufacturing, and go-to-market viability.

money_range

Expensive
High-quality diligence routinely costs five to six figures in billable hours—specialists, analysts, and repeated cycles of updates as new data emerges.

There’s a persistent gap between science, commercialization reality, and investment decisions—making the “valley of death” hard to cross.

OUR OFFERING

AUGMENTING – NOT REPLACING

YOUR
SCIENTIFIC
EXPERTISE

VENTURE
SCIENTIST

OUR
VENTURING AI
PLATFORM

A true scientist–AI hybrid: your deep technical expertise, amplified with our venture-grade commercialization and business intelligence.

HOW IT WORKS

FROM PITCH TO DECISION IN MINUTES

1

A diagram showing the different parts of a neuron, including the dendrites, cell body, axon, and axon terminals, illustrating how nerve signals travel through the neuron.

OPPORTUNITY

PRIORITIZE INNOVATION ELEMENTS

2

ASSESS EACH ELEMENT INDIVIDUALLY

3

Diagram showing data flow from marbles with labels to neural network, illustrating pattern recognition process.

DECISION

CONVERGE INTO ACTIONABLE PATHWAY

Fast doesn’t mean shallow: we evaluate each critical dimension separately, then reconcile tradeoffs into a single path forward.

OUR VENTURING AI ENGINE

OUR MULTI-AGENT RAG SYSTEM

Resources
Agent

Manufac
turability
Agent

Publication
Proximity
Agent

Technology Maturity
Agent

Patents
Proximity
Agent

Regulatory
Pathway
Agent

Business
Strategy
Agent

Team
Assessment
Agent

Sustaina
bility
Agent

Markets
Agent

Commercial
Scoring
Agent

Market Fit
Agent

A diagram showing the different parts of a neuron, including the dendrites, cell body, axon, and axon terminals, illustrating how nerve signals travel through the neuron.

Prioritization
Agent

low_priority

Prioritization
We deconstruct your core objective into prioritized commercial and technical elements using our Prioritization Agent.

biotech

Assessment
With a suite of specialized agents we assess maturity levels and identifies gaps across key domains.
Diagram showing data flow from marbles with labels to neural network, illustrating pattern recognition process.

Convergent
Agent

join

Convergence
With our Convergent Agent, we synthesize these insights into an actionable pathway, leading to a decisive recommendation.

WHAT YOU GET

KNOW WHAT IT TAKES – BEFORE YOU INVEST

Excerpt from a real, redacted Executive Summary of a commercialization report produced during a VentureScientist.ai assessment.

readiness_score

Readiness Score
Quantified commercialization maturity across science, IP, market, regulatory, and execution drivers.

money_bag

Time & Capital Estimate
Summarizes investment to date and forecasts time and funding required to reach milestones.

air

Decision Memo + Pathway
Milestone roadmap across 1–5 years, with decision gates, risks, and priorities.

storefront

Go-to-Market Blueprint
Defines best-fit market, positioning, buyer, and the route to commercialization or partnership.

BUILT FOR DEEP-TECH TRANSLATION

COMMERCIALIZATION IS DOMAIN-SPECIFIC

Life sciences
& Pharma

Advanced
Materials

Aerospace &
Defense

Clean
Energy

Each sector runs on different rules—risk, timelines, regulation, unit economics, and adoption. We apply the right diligence lens for each market.

HOW WE WORK

FROM INITIAL ASSESSMENT TO OPERATIONALIZED DILIGENCE

1

PILOT ASSESSMENT

We evaluate a defined set of opportunities (or one flagship technology) and deliver a decision-ready package: maturity score, time & capital estimate, go-to-market blueprint, and a 1–5 year milestone pathway.

2

EXPANSION

We tailor the workflow to your context—your evaluation criteria, templates, scoring dimensions, and decision gates—so assessments become consistent across projects and stakeholders.

3

INTEGRATION

We operationalize VentureScientist inside your process: governance, repeatable reporting, audit trail, and (when needed) integration with your systems and knowledge sources.

OUR TEAM

DEMOCRATIZING COMMERCIALIZATION KNOWLEDGE

We understand the complexity of deep-tech decision-making.

VentureScientist is led by seasoned innovators with 40+ years’ combined experience in deep-tech R&D and commercialization. Drs. Zagit Gaymalov and Dennis Gilmore co-founded VentureScientist after decades guiding high-stakes innovation projects around the world. They are the inventors of the ICANVAS® and RECOPE® evaluation frameworks (adopted by NASA, NIH, DARPA) and have held leadership roles at Moffitt Cancer Center, RTI International, PPG Industries, and Shell. Our team’s expertise and track record ensure that VentureScientist is built on solid scientific and industry ground

Black and white portrait of a man in a suit with a beard, looking directly at the camera.
A black-and-white portrait of an elderly man smiling, wearing a collared shirt and a dark jacket, standing outdoors near a modern building with large windows.

Zagit Gaymalov, PhD

Co-Founder

  • Inventor of ICANVAS® and RECOPE® frameworks

  • Inventor of Neovasculgen® gene therapy (cambiogenplasmid)

Dennis Gilmore, PhD

Co-Founder

  • Former RTI International Executive

  • 40+ years in global tech commercialization

LinkedIn
LinkedIn

FAQs

What do you need from me to run an assessment?

1

We can start with whatever you have: a pitch deck, papers, patents, notes, or a short description. If materials are limited, we’ll begin with a structured intake and identify the minimum inputs needed for a reliable score and roadmap.

What will I receive at the end of the assessment?

2

You receive a decision-ready package: a commercialization maturity score, time & capital estimate, current vs future state assessment, go-to-market blueprint, and a 1–5 year milestone pathway with decision gates and priorities.

How do you handle confidentiality and IP?

3

Confidential by default. We only use the materials you choose to share for your assessment, and we can work under an NDA. Your information stays private and is not shared with other clients.

Is VentureScientist.ai replacing experts or making the final decision?

4

No—VentureScientist.ai accelerates and standardizes diligence. It provides structured analysis, assumptions, and an evidence-backed pathway so you (and your stakeholders) can make faster, higher-confidence decisions.

Is my data used to train your models?

5

No—your materials are used only to generate your assessment. We do not train shared/public models on client-provided confidential data. If you opt in to improving the system, we can use anonymized, non-confidential feedback and metadata under explicit permission.

SCHEDULE A DEMO